Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.

Autor: Rannikko JH; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Turku Doctoral Program of Molecular Medicine, University of Turku, Turku, Finland., Verlingue L; Institut Gustave Roussy, Paris and Centre Leon Berard in Lyon, Lyon, France., de Miguel M; START-CIOCC HM Sanchinarro, Madrid, Spain., Pasanen A; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Robbrecht D; Erasmus Medical Center/Cancer Institute, Rotterdam, the Netherlands., Skytta T; Tampere University Hospital, Tampere, Finland., Iivanainen S; Oulu University Hospital, University of Oulu, Oulu, Finland., Shetty S; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Ma YT; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Graham DM; The Christie NHS Foundation Trust, Manchester, UK., Arora SP; Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA., Jaakkola P; Department of Oncology, Turku University Hospital and University of Turku, Turku, Finland., Yap C; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK., Xiang Y; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mandelin J; Faron Pharmaceuticals Ltd, Turku, Finland., Karvonen MK; Faron Pharmaceuticals Ltd, Turku, Finland., Jalkanen J; Faron Pharmaceuticals Ltd, Turku, Finland., Karaman S; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland., Koivunen JP; Oulu University Hospital, University of Oulu, Oulu, Finland; Faron Pharmaceuticals Ltd, Turku, Finland., Minchom A; Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK., Hollmén M; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Faron Pharmaceuticals Ltd, Turku, Finland. Electronic address: maijal@utu.fi., Bono P; Terveystalo Finland and University of Helsinki, Helsinki, Finland. Electronic address: petri.bono@terveystalo.com.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2023 Dec 19; Vol. 4 (12), pp. 101307. Date of Electronic Publication: 2023 Dec 05.

Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice.

Autor: Heinolainen K; Novartis Finland Oy, Espoo, Finland., Saarinen S; Novartis Finland Oy, Espoo, Finland., Vertuani S; Novartis Sverige AB, Kista, Sweden., Ellonen A; Department of Oncology, Turku University Central Hospital, Turku, Finland., Karlsson A; Auria Biobank and University of Turku, Turku, Finland., Utriainen M; Comprehensive Cancer Center, Helsinki University Central Hospital, Helsinki, Finland., Carlqvist P; Nordic Market Access, Stockholm, Sweden., Mandelin J; Faron Pharmaceuticals, Turku, Finland., Holm B; Novartis Sverige AB, Kista, Sweden. babbo.holm@gmail.com.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Sep; Vol. 149 (11), pp. 9139-9149. Date of Electronic Publication: 2023 May 13.

IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IκBζ-dependent induction of ELF3.

Autor: Kouri VP; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki.; Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital., Olkkonen J; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki., Nurmi K; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki., Peled N; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki., Ainola M; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki., Mandelin J; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki., Nordström DC; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki.; Department of Internal Medicine and Rehabilitation., Eklund KK; Department of Medicine, University of Helsinki and Helsinki University Hospital.; Translational Immunology Research Program, Research Programs Unit, University of Helsinki.; Inflammation Center, Division of Rheumatology, Helsinki University Hospital.; ORTON Orthopaedic Hospital of the Orton Foundation, Helsinki, Finland.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2023 Feb 01; Vol. 62 (2), pp. 872-885.

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

Autor: Bono, P., Minchom, A., Shetty, S., Ma, Y.T., Cruz, R., de Jonge, M.J.A., Yap, C., Pasanen, A., Skytta, T., Iivanainen, S.M.E., Verlingue, L., Jaakkola, P., de Miguel, M.J., Arora, S., Graham, D., Jalkanen, S., Hollmen, M., Mandelin, J., Karvonen, M.K., Kauko, T., Koivunen, J.P.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S1313-S1313